Perry J. Sternberg Joins Sydnexis as Chief Executive Officer

News, SydnexisBy Garrett Hamontree July 17, 2024

Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is excited to announce the appointment of Perry J. Sternberg as Chief Executive Officer and as a member of the Board of Directors. An accomplished pharma/biotech executive with over 30 years in the industry and 15 years in eye care, Perry will provide invaluable leadership experience to help guide Sydnexis’ strategic direction and next phase of growth.

Global Pharma Company, Santen, and Visionary Portfolio Company, Sydnexis, Unite To Vanquish Childhood Myopia

License Deal, News, SydnexisBy Garrett Hamontree August 10, 2021

Global biopharmaceutical firm Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia. The agreement covers Europe, Middle East, and Africa (EMEA) region.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

News, SydnexisBy Garrett Hamontree August 10, 2021

Visionary Ventures led a $45MM round into its 12th portfolio company, Sydnexis. Sydnexis is a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi. The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.

Category Archives: Sydnexis